Novavax RSV F vaccine trial for women shows promise

Courtesy of transformingscience.com
A recent clinical trial of Novavax, Inc.'s RSV F-protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) involving women between the ages of 18 and 35 years old found that the vaccine improved the body's immune response. 

The randomized, blind, placebo-controlled Phase 2 clinical trial determined the safety as well as immunogenicity of two doses of the RSV F Vaccine, one with aluminum phosphate adjuvant and the other without. The study involved 330 women who were of childbearing age.

“These data are the foundation for our ongoing RSV F Vaccine development program to protect infants via maternal immunization,” Dr. Gregory Glenn, senior vice president of Research and Development for Novavax, said. “The RSV F Vaccine stimulated high levels of anti-F, PCA and microneutralizing antibodies. Further, our ad hoc analysis via Western Blot, together with our recent data in older adults, provides an additional indication that the vaccine-induced immunity can protect against RSV infections in humans. We look forward to announcing additional data from our trial of the RSV F Vaccine in pregnant women later this quarter, a key milestone in our strategy to develop a vaccine designed to protect infants via maternal immunization.”

Further details are available in the Journal of Infectious Disease.

Organizations in this story

Novavax 20 Firstfield Road Gaithersburg, MD - 20878

Get notified the next time we write about Novavax!